Cargando…

Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis

OBJECTIVE: To estimate the magnitude in which Parkinson’s disease (PD) symptoms and health- related quality of life (HRQoL) determined PD costs over a 4-year period. MATERIALS AND METHODS: Data collected during 3-month, each year, for 4 years, from the ELEP study, included sociodemographic, clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Martín, Pablo, Rodriguez-Blazquez, Carmen, Paz, Silvia, Forjaz, Maria João, Frades-Payo, Belén, Cubo, Esther, de Pedro-Cuesta, Jesús, Lizán, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689528/
https://www.ncbi.nlm.nih.gov/pubmed/26698860
http://dx.doi.org/10.1371/journal.pone.0145310
_version_ 1782406859720753152
author Martinez-Martín, Pablo
Rodriguez-Blazquez, Carmen
Paz, Silvia
Forjaz, Maria João
Frades-Payo, Belén
Cubo, Esther
de Pedro-Cuesta, Jesús
Lizán, Luis
author_facet Martinez-Martín, Pablo
Rodriguez-Blazquez, Carmen
Paz, Silvia
Forjaz, Maria João
Frades-Payo, Belén
Cubo, Esther
de Pedro-Cuesta, Jesús
Lizán, Luis
author_sort Martinez-Martín, Pablo
collection PubMed
description OBJECTIVE: To estimate the magnitude in which Parkinson’s disease (PD) symptoms and health- related quality of life (HRQoL) determined PD costs over a 4-year period. MATERIALS AND METHODS: Data collected during 3-month, each year, for 4 years, from the ELEP study, included sociodemographic, clinical and use of resources information. Costs were calculated yearly, as mean 3-month costs/patient and updated to Spanish €, 2012. Mixed linear models were performed to analyze total, direct and indirect costs based on symptoms and HRQoL. RESULTS: One-hundred and seventy four patients were included. Mean (SD) age: 63 (11) years, mean (SD) disease duration: 8 (6) years. Ninety-three percent were HY I, II or III (mild or moderate disease). Forty-nine percent remained in the same stage during the study period. Clinical evaluation and HRQoL scales showed relatively slight changes over time, demonstrating a stable group overall. Mean (SD) PD total costs augmented 92.5%, from €2,082.17 (€2,889.86) in year 1 to €4,008.6 (€7,757.35) in year 4. Total, direct and indirect cost incremented 45.96%, 35.63%, and 69.69% for mild disease, respectively, whereas increased 166.52% for total, 55.68% for direct and 347.85% for indirect cost in patients with moderate PD. For severe patients, cost remained almost the same throughout the study. For each additional point in the SCOPA-Motor scale total costs increased €75.72 (p = 0.0174); for each additional point on SCOPA-Motor and the SCOPA-COG, direct costs incremented €49.21 (p = 0.0094) and €44.81 (p = 0.0404), respectively; and for each extra point on the pain scale, indirect costs increased €16.31 (p = 0.0228). CONCLUSIONS: PD is an expensive disease in Spain. Disease progression and severity as well as motor and cognitive dysfunctions are major drivers of costs increments. Therapeutic measures aimed at controlling progression and symptoms could help contain disease expenses.
format Online
Article
Text
id pubmed-4689528
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-46895282015-12-31 Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis Martinez-Martín, Pablo Rodriguez-Blazquez, Carmen Paz, Silvia Forjaz, Maria João Frades-Payo, Belén Cubo, Esther de Pedro-Cuesta, Jesús Lizán, Luis PLoS One Research Article OBJECTIVE: To estimate the magnitude in which Parkinson’s disease (PD) symptoms and health- related quality of life (HRQoL) determined PD costs over a 4-year period. MATERIALS AND METHODS: Data collected during 3-month, each year, for 4 years, from the ELEP study, included sociodemographic, clinical and use of resources information. Costs were calculated yearly, as mean 3-month costs/patient and updated to Spanish €, 2012. Mixed linear models were performed to analyze total, direct and indirect costs based on symptoms and HRQoL. RESULTS: One-hundred and seventy four patients were included. Mean (SD) age: 63 (11) years, mean (SD) disease duration: 8 (6) years. Ninety-three percent were HY I, II or III (mild or moderate disease). Forty-nine percent remained in the same stage during the study period. Clinical evaluation and HRQoL scales showed relatively slight changes over time, demonstrating a stable group overall. Mean (SD) PD total costs augmented 92.5%, from €2,082.17 (€2,889.86) in year 1 to €4,008.6 (€7,757.35) in year 4. Total, direct and indirect cost incremented 45.96%, 35.63%, and 69.69% for mild disease, respectively, whereas increased 166.52% for total, 55.68% for direct and 347.85% for indirect cost in patients with moderate PD. For severe patients, cost remained almost the same throughout the study. For each additional point in the SCOPA-Motor scale total costs increased €75.72 (p = 0.0174); for each additional point on SCOPA-Motor and the SCOPA-COG, direct costs incremented €49.21 (p = 0.0094) and €44.81 (p = 0.0404), respectively; and for each extra point on the pain scale, indirect costs increased €16.31 (p = 0.0228). CONCLUSIONS: PD is an expensive disease in Spain. Disease progression and severity as well as motor and cognitive dysfunctions are major drivers of costs increments. Therapeutic measures aimed at controlling progression and symptoms could help contain disease expenses. Public Library of Science 2015-12-23 /pmc/articles/PMC4689528/ /pubmed/26698860 http://dx.doi.org/10.1371/journal.pone.0145310 Text en © 2015 Martinez-Martín et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Martinez-Martín, Pablo
Rodriguez-Blazquez, Carmen
Paz, Silvia
Forjaz, Maria João
Frades-Payo, Belén
Cubo, Esther
de Pedro-Cuesta, Jesús
Lizán, Luis
Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis
title Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis
title_full Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis
title_fullStr Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis
title_full_unstemmed Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis
title_short Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis
title_sort parkinson symptoms and health related quality of life as predictors of costs: a longitudinal observational study with linear mixed model analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689528/
https://www.ncbi.nlm.nih.gov/pubmed/26698860
http://dx.doi.org/10.1371/journal.pone.0145310
work_keys_str_mv AT martinezmartinpablo parkinsonsymptomsandhealthrelatedqualityoflifeaspredictorsofcostsalongitudinalobservationalstudywithlinearmixedmodelanalysis
AT rodriguezblazquezcarmen parkinsonsymptomsandhealthrelatedqualityoflifeaspredictorsofcostsalongitudinalobservationalstudywithlinearmixedmodelanalysis
AT pazsilvia parkinsonsymptomsandhealthrelatedqualityoflifeaspredictorsofcostsalongitudinalobservationalstudywithlinearmixedmodelanalysis
AT forjazmariajoao parkinsonsymptomsandhealthrelatedqualityoflifeaspredictorsofcostsalongitudinalobservationalstudywithlinearmixedmodelanalysis
AT fradespayobelen parkinsonsymptomsandhealthrelatedqualityoflifeaspredictorsofcostsalongitudinalobservationalstudywithlinearmixedmodelanalysis
AT cuboesther parkinsonsymptomsandhealthrelatedqualityoflifeaspredictorsofcostsalongitudinalobservationalstudywithlinearmixedmodelanalysis
AT depedrocuestajesus parkinsonsymptomsandhealthrelatedqualityoflifeaspredictorsofcostsalongitudinalobservationalstudywithlinearmixedmodelanalysis
AT lizanluis parkinsonsymptomsandhealthrelatedqualityoflifeaspredictorsofcostsalongitudinalobservationalstudywithlinearmixedmodelanalysis
AT parkinsonsymptomsandhealthrelatedqualityoflifeaspredictorsofcostsalongitudinalobservationalstudywithlinearmixedmodelanalysis